All In Biotech

Drug Trial Radar · NCT00224874

Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)

Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (ONTAK), and Pentostatin in Combination With Corticosteroids (BMT CTN #0302)

Last checked: Nov 19, 2026Latest source record: Nov 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

180

Actual

Start

Sep 2005

Primary completion

Jan 2009

Study completion Jun 2012

Sponsor

Sponsor type
NIH
Collaborators
National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Network
First posted
Sep 23, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a randomized Phase II, four arm treatment trial. The primary purpose of the study is to define new agents with promising activity against acute graft-versus-host disease (GVHD) suitable for testing against corticosteroids alone in a subsequent Phase III trial.

Conditions

  • Graft vs Host Disease
  • Immune System Disorders

Interventions

  • EtanerceptDrug

    Etanercept \[25 mg subcutaneously twice weekly for up to 4 weeks; discontinue if in complete response by 4 weeks\].

  • Mycophenolate MofetilDrug

    Mycophenolate mofetil (MMF) \[20 mg/kg (maximum 1 gm) orally or intravenously twice daily; continue through prednisone taper, then taper MMF over 4 weeks\].

  • Denileukin DiftitoxDrug

    Denileukin Diftitox (ONTAK®) \[9 mcg/kg intravenously Days 1, 3, 5, 15, 17, 19\].

  • PentostatinDrug

    Pentostatin \[1.5 mg/m2 daily for 3 days; Days 1-3 and repeat Days 15-17

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Complete Response (CR) at Day 28 of TherapyTime frame: Measured at Day 28

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California

  • University of California

    San Diego, California

  • Stanford Hospital and Clinics

    Stanford, California

  • University of Florida College of Medicine (Shands)

    Gainesville, Florida

  • Johns Hopkins/SKCCC

    Baltimore, Maryland

  • DFCI/Brigham & Women's Hospital

    Boston, Massachusetts

  • University of Michigan Medical Center

    Ann Arbor, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • Washington University/Barnes Jewish Hospital

    St Louis, Missouri

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Duke University Medical Center (Peds)

    Durham, North Carolina

  • University Hospitals of Cleveland/Case Western

    Cleveland, Ohio

  • Oregon Health Sciences University

    Portland, Oregon

  • University of Pennsylvania Cancer Center

    Philadelphia, Pennsylvania

  • University of Texas/MD Anderson CRC

    Houston, Texas

  • Texas Transplant Institute

    San Antonio, Texas

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.